Key Points
- Tempus AI CFO James William Rogers sold 26,313 shares at an average price of $60, generating $1.58 million. The Rule 10b5-1 sale was intended to cover tax withholding tied to vested equity awards, leaving him with 106,024 shares.
- Tempus AI’s latest quarter exceeded expectations, reporting a loss of $0.04 per share versus the projected $0.14 loss and revenue of $382.49 million, up 21.6% year over year.
- Analyst sentiment remains mixed: BTIG raised its price target to $80 and maintained a Buy rating, while the broader analyst consensus is Hold with an average target of $65.69. The stock recently opened at $66.65.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CAO Ryan Bartolucci sold 6,175 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $306,341.75. Following the sale, the chief accounting officer owned 67,866 shares in the company, valued at approximately $3,366,832.26. This represents a 8.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Tempus AI Price Performance
NASDAQ:TEM opened at $66.65 on Friday. The stock has a market capitalization of $12.03 billion, a PE ratio of -46.28 and a beta of 3.58. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32. The firm has a fifty day simple moving average of $52.44 and a 200 day simple moving average of $51.21. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06.
Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company's quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.22) earnings per share. On average, research analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.
Key Tempus AI News
Here are the key news stories impacting Tempus AI this week:
- Positive Sentiment: BTIG raised its price target to $80 from $70 and reaffirmed a “Buy” rating. The new target implies approximately 20% upside from the referenced price and provides a direct catalyst for buying. BTIG raises Tempus AI price target
- Positive Sentiment: Investors are increasingly focused on Tempus AI’s approximately $1.5 billion all-stock acquisition of Personalis. Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
- Positive Sentiment: Reported progress involving Moderna and Merck in cancer vaccines has improved sentiment toward genomic-data providers and made Tempus’ Personalis strategy appear more timely. The benefit to TEM is indirect, but the developments support the company’s oncology growth narrative. Tempus AI and cancer vaccine developments
- Positive Sentiment: Call-option volume reached 40,671 contracts, about 57% above typical activity, signaling bullish speculation and potentially amplifying momentum.
- Neutral Sentiment: TEM’s move above key moving averages has been described as a possible short squeeze. This can support further gains, but it also raises volatility and reversal risk. Tempus AI technical rally
- Negative Sentiment: Several executives sold shares, including CEO Eric Lefkofsky, CFO James William Rogers and EVP Andrew Polovin. The sales totaled substantial amounts and reduced their holdings, which can concern investors. However, the transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.
Institutional Investors Weigh In On Tempus AI
Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company's stock valued at $605,772,000 after purchasing an additional 817,014 shares during the last quarter. ARK Investment Management LLC increased its stake in shares of Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company's stock worth $446,275,000 after purchasing an additional 381,816 shares during the period. GC Wealth Management RIA LLC acquired a new stake in Tempus AI during the 4th quarter worth approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company's stock valued at $195,636,000 after purchasing an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. boosted its stake in Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company's stock valued at $195,549,000 after purchasing an additional 821,490 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the stock. BTIG Research raised their target price on shares of Tempus AI from $70.00 to $80.00 and gave the company a "buy" rating in a research note on Thursday. Stifel Nicolaus dropped their price objective on Tempus AI from $60.00 to $50.00 and set a "hold" rating on the stock in a research note on Monday, August 3rd. Wall Street Zen raised Tempus AI from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. HC Wainwright decreased their target price on Tempus AI from $64.00 to $56.00 and set a "buy" rating on the stock in a report on Monday, August 3rd. Finally, Weiss Ratings upgraded Tempus AI from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $65.69.
Get Our Latest Report on Tempus AI
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
